Avicanna Reports Q2 2024 Page 1

Posted on August 14, 2024 by Vaseline

Q2 2024 revenue of $6.1 million, up 85% from Q2 2023
Completion of Two Real-World Evidence Trials on Epidermolysis Bullosa and Musculoskeletal Pain

TORONTO, August 14, 2024 (GLOBE NEWSWIRE) — Avicanna Inc. (“Avicanna” or “Company) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN) a biopharmaceutical company focused on the development, manufacturing and commercialization of plant-based cannabinoid products, reports second quarter 2024 results.

Related Posts

Cloudera is a platform for octopus for the development of research data for combined hybrids Cloud data file

So keep in touch with your intestinal health

Golden Bears play today for the Class AA title | News, sports, jobs